Cahaba Dermatology, Hoover, Alabama, 35244, United States - 29 Nov `23Povorcitinib Tablets for Nonsegmental Vitiligo

Povorcitinib Tablets for Nonsegmental Vitiligo

Official title: A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo

Status: Closed to new participants

Description:

This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.

Phase: Phase 3.

What is being studied: Drug: Povorcitinib; Drug: Placebo.

Who can take part: ages 18 Years, 467 participants planned.

Enrollment status: Closed to enrollment. The study starts 29 November 2023 and expected to finish 24 February 2027.

Source: ClinicalTrials.gov, NCT06113445 (https://clinicaltrials.gov/study/NCT06113445).

Start date: November 29, 2023

Completion date: February 24, 2027

Organizer: Incyte Corporation

Link: https://clinicaltrials.gov/study/NCT06113445

The registry does not list a contact for this study. Use the link above to reach the study record on ClinicalTrials.gov.

Clinical Trial Alerts

Sign up and be the first to know about updates on this trial.

This request will be sent with the trial reference Povorcitinib Tablets for Nonsegmental Vitiligo . By submitting you agree to our Privacy Policy.

FAQOther Questions